Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
Effectiveness and Safety of Rivaroxaban Compared to Low Molecular-Weight Heparin in Patients with Cancer-Associated Venous Thromboembolism: A Real-World Analysis.
2020
Research Type: Poster/Presentation
Do Differences in Baseline Clinical Severity of Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage Predict Andexanet Alfa Versus Four-Factor Prothrombin Complex Concentrate Administration?
2020
Research Type: Poster/Presentation
“FOUR-YEAR INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ATRIAL FIBRILLATION PATIENTS WITH OR AT HIGH RISK FOR ATHEROSCLEROSIS”. Event: ACC 2020, Chicago.
2020
Research Type: Poster/Presentation
“Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease”. Event: ESC Congress 2019, Paris.
2019
Research Type: Poster/Presentation
“Case clinic sessions: Tackling the challenge: High-risk NVAF patients”
2019
Research Type: Poster/Presentation
What Proportion of Hospitalizations in Acute Medically Ill Patients Qualify for Extended Thromboprophylaxis with Oral Anticoagulation?
2019
Research Type: Poster/Presentation
Safety and Effectiveness of Factor Xa Inhibitors Versus Warfarin in Nonvalvular Atrial Fibrillation Patients at High-Risk for Falls
2019
Research Type: Poster/Presentation
“Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis”. Event: ASH 2019, Orlando.
2019
Research Type: Poster/Presentation
“Effectiveness and Safety of Rivaroxaban and Warfarin for Prevention of Major Adverse Cardiovascular or Limb Events in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes”. Event: ISTH 2019, Melbourne.
2019
Research Type: Poster/Presentation
“Rivaroxaban Versus Warfarin and Renal Outcomes in Non-valvular Atrial Fibrillation Patients with Diabetes”. Event: ISTH 2019, Melbourne.
2019
Research Type: Poster/Presentation
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study
2018
Research Type: Poster/Presentation
Effectiveness and Safety of Rivaroxaban versus Low Molecular-weight Heparin for Treatment of Cancer-associated Thromboembolism
2018
Research Type: Poster/Presentation
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
2018
Research Type: Poster/Presentation
Translating real world evidence into your clinical practice for your multi-morbid patient
2018
Research Type: Poster/Presentation
Effectiveness and Safety of Outpatient Rivaroxaban versus Warfarin in Patients with Provoked Acute Venous Thromboembolism
2018
Research Type: Poster/Presentation
Comparative Efficacy and Safety of Anticoagulation for the Treatment of Cancer-associated Thrombosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
2018
Research Type: Poster/Presentation
Cost and Inpatient Burden of Peripheral Artery Disease: Findings From the National Inpatient Sample
2018
Research Type: Poster/Presentation
Indexing performance measure codes to enhance perceived value of EPC reports.
2018
Research Type: Poster/Presentation
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and Heart Failure
2018
Research Type: Poster/Presentation